1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Locally advanced microsatellite instability-high esophagogastric cancer: Are we ready to change our treatment paradigm?
    Editorial

    Ilson, D. H.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Current management of advanced hepatocellular carcinoma
    Review

    Abou-Alfa, G. K.; Huitzil-Melendez, F. D.; O’Reilly, E. M.; Saltz, L. B.
    Gastrointestinal Cancer Research (2025)

    Fulltext@MSK | Save
  • Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma
    Journal Article

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma
    Journal Article

    Wolchok, J. D.; Chiarion-Sileni, V.; Rutkowski, P.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Queirolo, P.; Dummer, R.; Butler, M. O.; Hill, A. G.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01
    Journal Article

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas, S.; De Laurentiis, M.; Wang, S.; Martínez Jañez, N.; Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Heinrich, M. C.; Blay, J. V.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors
    Meeting Abstract

    Lakhani, N. J.; Melisi, D.; Subbiah, V.; Ammakkanavar, N. R.; O'Reilly, E. M.; Cassier, P. A.; Wainberg, Z. A.; Duffy, A. G.; Patnaik, A.; Fujiwara, Y.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Sohal, D.; Reiss, K. A.; Sanford, N. N.; Allegra, C.; Colby, S.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Harding, J. J.; Macarulla, T.; Pant, S.; Wu, X.; Garfin, P. M.; Okusaka, T.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
    Meeting Abstract

    Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save